| Jessica G Parker, SLP | |
|
17830 New Hampshire Ave Ste 300, Ashton, MD 20861-3644 | |
| (301) 323-8486 | |
| (240) 422-8283 |
| Full Name | Jessica G Parker |
|---|---|
| Gender | Female |
| Speciality | Qualified Speech Language Pathologist |
| Experience | 19 Years |
| Location | 17830 New Hampshire Ave Ste 300, Ashton, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790811495 | NPI | - | NPPES |
| 212044501 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 06588 (Maryland) | Primary |
| Provider Name | Adult Speech Therapy Services Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1063979664 PECOS PAC ID: 4082947718 Enrollment ID: O20190611002380 |
News Archive
Genentech, a member of the Roche Group, today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
The "crippling" and "growing burden" of communicable diseases such as dengue fever, polio, or meningitis is not being sufficiently addressed in developing countries, according to "The Epidemic Divide," a report released Monday by the International Federation of Red Cross and Red Crescent Societies (IFRC), AFP/Google.com reports. According to the report, resources to deal with existing epidemics are "scarce."
Cardiovascular disease was the leading cause of death in Florida in 2005, accounting for approximately 35 percent of all deaths in the state. People with heart disease are at a high risk for serious and potentially life-threatening complications from the flu.
A pair of studies at UCLA's Jonsson Cancer Center that takes laboratory science to the patients' bedside found that combining the molecularly targeted therapy Herceptin with a specific chemotherapy combination resulted in significant tumor response rates and longer relapse-free periods in women with an aggressive form of advanced breast cancer.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jessica G Parker, SLP 17830 New Hampshire Ave Ste 300, Ashton, MD 20861-3644 Ph: (301) 323-8486 | Jessica G Parker, SLP 17830 New Hampshire Ave Ste 300, Ashton, MD 20861-3644 Ph: (301) 323-8486 |
News Archive
Genentech, a member of the Roche Group, today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
The "crippling" and "growing burden" of communicable diseases such as dengue fever, polio, or meningitis is not being sufficiently addressed in developing countries, according to "The Epidemic Divide," a report released Monday by the International Federation of Red Cross and Red Crescent Societies (IFRC), AFP/Google.com reports. According to the report, resources to deal with existing epidemics are "scarce."
Cardiovascular disease was the leading cause of death in Florida in 2005, accounting for approximately 35 percent of all deaths in the state. People with heart disease are at a high risk for serious and potentially life-threatening complications from the flu.
A pair of studies at UCLA's Jonsson Cancer Center that takes laboratory science to the patients' bedside found that combining the molecularly targeted therapy Herceptin with a specific chemotherapy combination resulted in significant tumor response rates and longer relapse-free periods in women with an aggressive form of advanced breast cancer.
› Verified 6 days ago
Adult Speech Therapy Services Llc Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 17830 New Hampshire Ave Ste 300, Ashton, MD 20861 Phone: 301-323-8486 Fax: 240-422-8283 |